



美国华裔血液与肿瘤专家协会

## 6<sup>th</sup> Annual New York Oncology Forum

Saturday, November 16, 2019, 7:00 am - 5:00 pm

Sunday, November 17, 2019, 8:30 am - Noon

**Sheraton LaGuardia East Hotel**

135-20 39<sup>th</sup> Street, Flushing, NY 11354

CONFERENCE CHAIR

**Delong Liu, MD, PhD**

Professor of Medicine, *New York Medical College*  
Editor-in-Chief, *Journal of Hematology & Oncology*

CONFERENCE CO-CHAIR

**Yiwu Huang, MD, PhD**

Associate Professor of Medicine  
*Maimonides Medical Center*

[www.cahon.org](http://www.cahon.org)

# Sponsors

---

## Diamond

---



## Gold

---



## Silver

---



## Bronze

---



# Exhibitors

---

Abbvie  
AGIO Pharmaceuticals  
Alexion  
Amgen  
Astellas  
AstraZeneca  
Bao Tuan Yang Lao US 抱团养老  
BeiGene  
Bristol Myers Squibb  
Dova Pharmaceuticals  
Eisai  
EUSA Pharma  
Exelixis

Foundation Medicine  
Genentech  
Genomic Health  
Immunomedics  
Incyte  
Innocare Pharma  
Janssen Research & Development  
Janssen Biotech  
Jazz Pharmaceuticals  
Jiangsu Hengrui Medicine  
Junishi Top Alliance  
Lilly  
Merck

Novartis  
Pfizer  
Pharmacyclics  
Rigel  
Sanofi  
Seattle Genetics  
Servier Pharmaceuticals  
Taiho Oncology  
Takeda Oncology  
Teva Pharmaceuticals  
Verastem Oncology

# Contents

Forum Sponsors and Exhibitors.....	Inside Cover
About CAHON.....	1
Meeting Information.....	2
Program — Saturday, November 16, 2019.....	4
Annual Member Meeting and Awards Ceremony.....	7
Program — Sunday, November 17, 2019.....	8

## About CAHON

Founded by Chinese American Hematologists and Oncologists in 2005, the primary missions of CAHON are to foster communications amongst Chinese American medical professionals for the delivery of high-quality health care to patients with neoplastic and hematological diseases, and to promote medical information exchange between the United States and China in the field of hematology and oncology. CAHON strives to serve as a bridge among its members and between Chinese and American Hematology-Oncology communities for medical and educational exchange.

### Save the Dates!

#### CAHON 2019 SEMI-ANNUAL RECEPTION AND SYMPOSIUM (DURING ASH)

December 7, 2019

6:00 pm - 10:00 pm

Gaylord Palms, Kissimmee (Orlando), Florida

Email your first and last name and organization name to [info@cahon.org](mailto:info@cahon.org) to register.

#### CAHON COMMUNITY ONCOLOGY FORUM

February 15, 2020 • 7:00 am – 12:05 pm

Hyatt Regency Clearwater, Clearwater (Tampa), Florida

For more information and to register, visit <http://bit.ly/COF2020>.

#### 7TH IMMUNOTHERAPY OF CANCER CONFERENCE

April 2 – 4, 2020 • Munich, Germany

[www.itoc-conference.eu](http://www.itoc-conference.eu)

#### CAHON 2020 SEMI-ANNUAL RECEPTION AND SYMPOSIUM (DURING ASCO)

May 30, 2020

Chicago, Illinois

### CAHON Membership

Apply to become a CAHON member at [www.cahon.org](http://www.cahon.org).

#### VALUE OF A CAHON MEMBERSHIP

By joining CAHON you will have access to:

- A growing network of Chinese American professionals working in your field;
- A private WeChat group where you can submit clinical questions to respected colleagues who are knowledgeable in specific areas of hematology and oncology;
- Reduced or waived registration fees for all CAHON events and meetings along with priority hotel reservations;
- Members-only section of the CAHON website including the member directory; and
- Travel award opportunities.

#### MEMBER CATEGORIES

Active Membership, Associate Membership, Allied Membership  
Visit [www.cahon.org/membership](http://www.cahon.org/membership) for more information.

### The Story Behind the CAHON Logo

CAHON'S logo was designed by Drs. Weijing Sun, Ke Liu, and Jeffrey Ye, under the supervision of the CAHON Board. The design has the following elements and takes the following considerations:



- The overall shape represent the globe.
- The blue, white, red and yellow represent the colors of two nations' flags. China and the US.
- The yellow and red stripes above the blue, represent bridges. One of CAHON's key missions I to serve as bridge between Chinese American Hematology-Oncology communities for medical and educational exchange.
- The white space is in the shape of a heart. The hearts of our members continue to drive our mission to provide high quality patient care to everyone.



# Meeting Information

---

## The learning objectives are

- Updates on novel agents and regimens including cellular therapy and immune checkpoint blockers for cancer diagnosis and therapy;
- Updates and guidance for molecular diagnosis, drug development, and precision therapy;
- Recommendations and guidance on clinical training and career paths.

## Lifetime Achievement Award Committee

Lei Zheng, MD, PhD - *CAHON President*  
Chong-xian Pan, MD, PhD - *CAHON President-elect*  
David Chang, MD, PhD - *CAHON Chair*  
Wenru Song, MD, PhD - *CAHON Chair-elect*  
Delong Liu, MD, PhD - *Conference Chair*  
Yiwu Huang, MD, PhD - *Conference Co-chair*

## Fellow Travel Awards Committee

Wei Ding, MD, PhD - *Mayo Clinic*  
Siwen Hu-Lieskovan - *University of Utah Huntsman Cancer Institute*  
Lei Zheng, MD, PhD - *Johns Hopkins University*  
David Chang, MD, PhD - *East Virginia School of Medicine*  
Delong Liu, MD, PhD - *New York Medical College*  
Yiwu Huang, MD, PhD - *Maimonides Medical Center*

## Conference Volunteer Staff

Bo Yu, MD, PGY1 - *Lincoln Medical Center*  
Changchuan Charles Jiang, MD, PGY3 - *Mt Sinai St Luke's Hospital*  
Jiajia Zhang, MD, MPH - *Johns Hopkins University*  
Juanjuan Zhao, MD - *Zhengzhou University, China*  
Lei Deng, MD, PGY3 - *Jacobi Medical Center, Albert Einstein College of Medicine*  
Xuan Ge, MD, PhD, PGY3 - *Jacobi Medical Center, Albert Einstein College of Medicine*

## Speakers and Faculty:

Aiwu Ruth He, MD - *Georgetown University Medical Center*  
Anas Younes, MD - *Memorial Sloan Kettering Cancer Center*  
Bo Wang, MD - *Mt. Sinai Medical Center*  
Bo Zhao, MD - *University Hospitals Seidman Cancer Center, Ohio*  
Catherine Lai, MD - *Georgetown University Medical Center*  
Chong-xian Pan, MD, PhD - *CAHON President-elect, University of California at Davis*  
David Chang, MD, PhD - *CAHON Board Chair, East Virginia Medical School*  
Delong Liu, MD, PhD - *Westchester Medical Center/New York Medical College*  
Faye Yin, MD - *Western Maryland Health System*  
Fei Gu, MD - *New Mexico Cancer Care Associates*  
Gary Tian, MD, PhD - *West Cancer Center*

Haiyun Wang, MD - *University of Minnesota*  
Heng Xie, MD - *Salubris Pharmaceutical*  
Hong Zheng, MD, PhD - *Penn State University*  
Hongtao Liu, MD, PhD - *University of Chicago*  
Huiguo Edward Lin, MD - *University of Washington*  
Janice Min Lu, MD, PhD - *David Geffen School of Medicine*  
Jeffrey Pu, MD, PhD - *SUNY Upstate*  
Jia Ruan, MD, PhD - *Weill Cornell College of Medicine*  
Jiajia Zhang, MD, MPH - *Johns Hopkins University*  
Jijun Jane Liu, MD - *Illinois CancerCare*  
Jing Christine Ye, MD - *University of Michigan*  
Jingsong Zhang, MD, PhD - *H. Lee Moffitt Cancer Center*  
Jing-zhou Hou, MD, PhD - *University of Pittsburgh Medical Center*  
Jun Zhang, MD, PhD - *University of Kansas*  
Kanti Rai, MD - *Long Island Jewish Hospital*  
Ke Liu, MD, PhD - *CAHON*  
Kevin Shieh, MD - *Maimonides Medical Center*  
Kwok-Kin Wong, MD, PhD - *NYU Langone Health*  
Lan Mo, MD, PhD - *Maimonides Cancer Center*  
Lei Deng, MD - *Jacobi Medical Center Albert Einstein College of Medicine*  
Lei Zhang, PhD - *Denovo Biopharma*  
Lei Zheng, MD, PhD - *CAHON President, Johns Hopkins University*  
Liang Deng, MD, PhD - *Memorial Sloan Kettering Cancer Center*  
Ligeng Tian, MD, PhD - *Virginia Oncology Associates*  
Mary Li, MD - *Florida Cancer Specialists*  
Mei Tang, MD - *Greater Baltimore Medical Center*  
Min Sun, MD - *University of Pittsburgh Medical Center*  
Peter Jiang, MD - *Columbus Regional Health*  
Ping Gu, MD, PhD - *Memorial Sloan Kettering Cancer Center*  
Qi Feng, MD - *Hematologist & Oncologist, NY*  
Renbin Zhao, PhD - *Innocare Pharma*  
Richard Lin, MD - *Stony Brook University*  
Richard Xu, MD, PhD - *Hematologist & Oncologist, Flushing, NY*  
Ruirong Yuan, MD, PhD - *Adlai Nortye Pharma/New Jersey VA Medical Center*  
Sen-hong Zhuang, MD, PhD - *Janssen*  
Sheng Yao, PhD - *Junshi Top Alliance*  
Shenghong Wu, MD, PhD - *SUNY Stonybrook*  
Shuang Fu, MD - *Kirkland Cancer Center*  
Song Huang, PhD - *Beijing Institute of Life Sciences*  
Sundar Jagannath, MD, Mt. Sinai Medical Center  
Tian Zhang, MD, MHS - *Duke University Cancer Institute*  
Tianhong Li, MD, PhD - *University of California at Davis*  
Tong Dai, MD, PhD - *Roswell Park Memorial Institute*  
Tony Cheung, MD - *Hematologist & Oncologist, Long Island, NY*  
Wanqing Iris Zhi, MD, PhD - *Memorial Sloan Kettering Cancer Center*  
Weijing Sun, MD - *University of Kansas Medical Center*  
Wenqing Zhang, MD - *Illinois Cancer Care*  
Wenru Song, MD, PhD - *CAHON*



# Program — Saturday, November 16, 2019

---

## Registration

Time 6:30 – 8:30 am

## Breakfast and Visit Exhibitors

Time 6:30 – 8:30 am

## Satellite Breakfast Program

Time 7:00 – 8:00 am

Session Chair Yi Feng, MD - Hematologist and Oncologist, Louisville, KY

7:00 – 8:00 am **VYXEOS®: Improving Outcomes in Patients with Newly-Diagnosed Secondary AML**  
*Sponsored by Jazz Pharmaceuticals, Inc.*  
Catherine Lai, MD - Georgetown University Medical Center

**8:00 – 8:30 am** *Break and Visit Exhibitors Phoenix Ballroom Foyer and Phoenix Terrace  
Coffee in Boardroom East and Boardroom West*

## Plenary Session - 1

Time 8:30 am – Noon

Session Chairs Lei Zheng, MD, PhD - CAHON President, Johns Hopkins University  
David Chang, MD, PhD - CAHON Board Chair, East Virginia Medical School  
Chong-xian Pan, MD, PhD - CAHON President-elect, University of California at Davis  
Zihai Li, MD, PhD - The James, The Ohio State University

8:30 – 8:35 am **Welcome Remarks**  
Delong Liu, MD, PhD - New York Medical College

8:35 – 8:40 am **CAHON: Current Status and Future Initiatives**  
Lei Zheng, MD, PhD - CAHON President, Johns Hopkins University

8:40 – 9:20 am **CAHON Lifetime Achievement Award Lecture**  
**Current Therapy for CLL**  
Kanti Rai, MD - Long Island Jewish Hospital

9:20 – 10:00 am **Current Therapies for Multiple Myeloma**  
Sundar Jagannath, MD - Mt. Sinai Medical Center

10:00 – 10:30 am **Biopharma Forum**

Session Chairs Wenru Song, MD, PhD - Kira Pharma  
Sen-hong Zhuang, MD, PhD - Janssen  
Discussion Panel Song Huang, PhD - Beijing Institute of Life Sciences  
Yuxia Jia, MD, PhD - CAHON  
Ke Liu, MD, PhD - CAHON  
Heng Xie, MD - Salubris Pharmaceutical  
Sheng Yao, PhD - Junshi Top Alliance  
Ruirong Yuan, MD, PhD - Adlai Nortye  
Renbin Zhao, PhD - Innocare Pharma  
Lei Zhang, PhD - Denovo Biopharma  
Youxin Zhang - BeiGene

**10:30 – 10:50 am** *Break and Visit Exhibitors Phoenix Ballroom Foyer and Phoenix Terrace  
Coffee in Boardroom East and Boardroom West*

# Program — Saturday, November 16, 2019

---

<i>Session Chairs</i>	Zujun Li, MD - NYU Langone Health Ping Gu, MD, PhD - Memorial Sloan Kettering Cancer Center
10:50 – 11:35 am	<b>Novel Therapeutic Strategies for the Treatment of Lung Cancer</b> Kwok-Kin Wong, MD, PhD - NYU Langone Health
11:35 – 12:00 am	<b>CAHON Members' Clinical Trials</b> DeLong Liu, MD, PhD - Westchester Medical Center/New York Medical College Weijing Sun, MD - University of Kansas Medical Center Jing-zhou Hou, MD, PhD - University of Pittsburgh Medical Center Jing Christine Ye, MD - University of Michigan Jia Ruan, MD, PhD - Weill Cornell College of Medicine

## Satellite Lunch Program

<i>Time</i>	Noon – 1:00 pm
<i>Session Chair</i>	Huiguo Edward Lin, MD - University of Washington Gary Tian, MD, PhD - West Cancer Center
Noon – 1:00 pm	<b>Role of CABOMETYX® in Patients with Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma</b> <i>Sponsored by Exelixis</i> Shenghong Wu, MD, PhD - SUNY Stonybrook Aiwu Ruth He, MD - Georgetown University Medical Center
<b>1:00 – 1:20 pm</b>	<b>Break and Visit Exhibitors</b>

## Plenary Session – 2

<i>Time</i>	1:20 – 3:40 pm
<i>Session Chairs</i>	Jijun Jane Liu, MD - Illinois CancerCare Yixing Jiang, MD, PhD - University of Maryland
1:20 – 2:00 pm	<b>Current Management Strategies of DLBCL and Double Hit Lymphoma</b> Anas Younes, MD - Memorial Sloan Kettering Cancer Center
2:00 – 2:40 pm	<b>Rational Engineering of Immune-Activating Vaccinia Viruses to Overcome Resistance to Immune Checkpoint Blockade</b> Liang Deng, MD, PhD - Memorial Sloan Kettering Cancer Center
<b>2:40 – 3:00 pm</b>	<b>Break</b>
<i>Session Chair:</i>	Tong Dai, MD, PhD - Roswell Park Memorial Institute
3:00 – 3:40 pm	<b>Targeting Immune Checkpoints for AML Treatment</b> Hong Zheng, MD, PhD - Penn State University
<b>3:40 – 4:00 pm</b>	<b>Break and Visit Exhibitors</b>

# Program — Saturday, November 16, 2019

---

## Case Studies Clinical Hematology/Oncology Session


<i>Time</i>	4:00 – 5:00 pm
<i>Session Chairs</i>	Yue Zhang, MD, MPH - <i>SUNY Stony Brook</i> Wanqing Iris Zhi, MD, PhD - <i>Memorial Sloan Kettering Cancer Center</i>
4:00 – 5:00 pm	<b>Case Presentations</b>
<i>Discussion Panel</i>	Shuang Fu, MD - <i>Kirkland Cancer Center</i> Lan Mo, MD, PhD - <i>Maimonides Cancer Center</i> Tony Cheung, MD - <i>Hematologist &amp; Oncologist, Long Island, NY</i> Xiusheng Qin, MD, PhD - <i>Lima Memorial Hospital</i> Ligeng Tian, MD, PhD - <i>Virginia Oncology Associates</i> Xuan Huang, MD, PhD - <i>University Hospitals Siedman Cancer Center at Case Western Reserve University</i> Wenqing Zhang, MD - <i>Illinois CancerCare</i> Mei Tang, MD - <i>Greater Baltimore Medical Center</i> YongLi Lily Ji, MD, PhD - <i>MGH-Exeter</i> Fei Gu, MD - <i>New Mexico Cancer Care Associates</i> Yiqing Xu, MD - <i>Maimonides Cancer Center</i> Min Sun, MD - <i>University of Pittsburgh Medical Center</i> Hongtao Liu, MD, PhD - <i>University of Chicago</i> Zhihong Julia Zhang, MD, PhD - <i>University of Arkansas</i>



# Annual Member Meeting and Awards Ceremony

*for CAHON members only*

The Gallery Room, 7th Floor  
Sheraton La Guardia East  
Saturday, November 16, 2019 • 5:00 – 9:00 pm



**Kanti Rai, MD**



## **Lifetime Achievement Award**

Recognizing significant contributions to the field through work that has a lasting impact on hematology and oncology. This year's winner has also served as a role model and mentor to many CAHON members over the years.



**Jing-zhou Hou, MD, PhD**



**Sen-hong Zhuang, MD, PhD**

## **Outstanding Service Awards**

Recognizing significant contributions to CAHON's development and mission. This year's winners have dedicated countless hours to support CAHON activities for many years.

## **2019 Fellow Travel Awards**

*Congratulations to this year's awardees!*

Haiyun Wang, MD - University of Minnesota  
Shijia Zhang, MD, PhD - University of Minnesota  
Zhihong Julia Zhang, MD, PhD - University of Arkansas

# Program — Sunday, November 17, 2019

---

## Registration

Time 8:00 – 9:00 am

## Breakfast

Time 8:00 – 9:30 am

## Satellite Breakfast Program

Time 8:30 – 9:30 am

Session Chair Yiyi Yan, MD, PhD - *Mayo Clinic*

8:30 – 9:30 am **The Role of the Oncotype AR-V7 Nucleus Detect test in mCRPC**

*Sponsored by Genomic Health*

Tian Zhang, MD, MHS - *Duke University Cancer Institute*

## Plenary Session - 3

Time 9:30 am – Noon

Session Chairs Tianhong Li, MD, PhD - *University of California at Davis*

Jeffrey Pu, MD, PhD - *SUNY Upstate*

9:30 – 10:00 am **Advances in Her2 Positive Breast Cancer**

Janice Min Lu, MD, PhD - *David Geffen School of Medicine*

**10:00 – 10:20 am Break**

10:20 – 11:00 am **Trainee Session**

Session Chairs Yucai Wang, MD, PhD - *Mayo Clinic*

Bo Wang, MD - *Mt. Sinai Medical Center*

10:20 – 10:30 am **Pathological Complete Response Following Neoadjuvant Chemotherapy in Operable Breast Cancer Patients: Is Obesity a Predictive Factor?**

Haiyun Wang, MD, Fellow - *University of Minnesota*

10:30 – 10:40 am **Mortality of Lung Cancer as a Second Primary Malignancy**

Lei Deng, MD, Resident (PGY3) - *Jacobi Medical Center, Albert Einstein College of Medicine*

10:40 – 10:50 am **Response to Immune Checkpoint Inhibitor Treatment in a Mixed Group of Patients with Platinum Sensitive and Refractory Cervical Cancer**

Kevin Shieh, MD, Resident - *Maimonides Medical Center*

10:50 – 11:00 am **Oral Antibiotic Use and Risk of Colorectal Cancer in the United Kingdom, 1989-2012: A Matched Case - Control Study**

Jiajia Zhang, MD, MPH - *Johns Hopkins University*

# Program — Sunday, November 17, 2019

11:00 – Noon

## Clinical Trials Consortium: An Open Discussion

Delong Liu, MD, PhD - *Westchester Medical Center/New York Medical College*  
Bo Zhao, MD - *University Hospitals Seidman Cancer Center, Ohio*

### Discussion Panel

Qi Feng, MD - *Hematologist & Oncologist, NY*  
William Li, MD, MSc - *Queens Hospital Center*  
Richard Xu, MD, PhD - *Hematologist & Oncologist, Flushing, NY*  
Xinhua Zhu, MD, PhD - *Northwell Health and Zucker School of Medicine*  
Min Sun, MD - *University of Pittsburgh Medical Center*  
Gary Tian, MD, PhD - *West Cancer Center*  
Richard Lin, MD - *Stony Brook University*  
Mary Li, MD - *Florida Cancer Specialists*  
Peter Jiang, MD, PhD - *Columbus Regional Health*  
Wenqing Zhang, MD - *Illinois Cancer Care*  
Ying Zhuo, MD - *Kadlec Hematology & Oncology Clinic*  
Faye Yin, MD - *Western Maryland Health System*  
Jun Zhang, MD, PhD - *University of Kansas*

## Closing Remarks

Yiwu Huang, MD, PhD - *Maimonides Medical Center*



**Rethink the potential of your secondary AML (sAML) patients**

**“I SAML READY TO BEAT THIS”**

David G, diagnosed with sAML

**Approximately 1 in 3 patients diagnosed with AML has sAML, which is historically associated with a poor prognosis<sup>1-3</sup>**

To properly identify sAML subtypes AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML (t-AML), it is important to understand the following:

- If a patient’s medical history shows they have been previously diagnosed with MDS or MDS/MPN, they may be diagnosed with the sAML subtype AML-MRC<sup>4</sup>
- For patients who cannot be diagnosed through their medical history, consider ordering tests for morphologic evaluation as well as cytogenetic analysis (karyotype), among other recommended tests<sup>5</sup>
  - Specifically, order an AML panel and an MDS panel<sup>6,7</sup>

**Consider a treatment plan with curative intent for appropriate patients—treating with chemotherapy plus HSCT is an opportunity to improve outcomes<sup>8,9</sup>**

**Changing the future of sAML starts today. RETHINK **SAML**.COM**

AML=acute myeloid leukemia; HSCT=hematopoietic stem cell transplant; MDS=myelodysplastic syndromes; MPN=myeloproliferative neoplasms.

**References:** 1. Nagel G, Weber D, Fromm E, et al; German Austrian AML Study Group (AMLSG). Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG Bio). *Ann Hematol*. 2017;96(12):1993-2003. 2. Leone G, Mele L, Pulsoni A, et al. The incidence of secondary leukemias. *Haematologica*. 1999;84(10):937-945. 3. Granfeldt Østgård LS, Medeiros BC, Sengelov H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. *J Clin Oncol*. 2015;33(31):3641-3649. 4. Miesner M, Haferlach C, Bacher U, et al. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as “AML not otherwise specified” (AML-NOS) or “AML with myelodysplasia-related changes” (AML-MRC). *Blood*. 2010;116(15):2742-2751. 5. Arber DA, Borowitz MJ, Cessna M, et al. Initial diagnostic workup of acute leukemia: guideline from the College of American Pathologists and the American Society of Hematology. *Arch Pathol Lab Med*. 2017;141(10):1342-1393. 6. Xu Y, Li Y, Xu Q, et al. Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing. *Oncotarget*. 2017;8(47):82475-82490. 7. Ossenkoppele G, Montesinos P. Challenges in the diagnosis and treatment of secondary acute myeloid leukemia. *Crit Rev Oncol Hematol*. 2019;138:6-13. 8. Wang ES. Treating acute myeloid leukemia in older adults. *Hematology Am Soc Hematol Educ Program*. 2014;2014(1):14-20. 9. Lipof JJ, Loh KP, O’Dwyer K, et al. Allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia. *Cancers (Basel)*. 2018;10(6):179.

Jazz Pharmaceuticals

©2019 Jazz Pharmaceuticals AML-0086 Rev0719

TAGRIS  
**DON'T MISS THE  
NEW DATA**



**TAGRIS**<sup>®</sup>  
osimertinib



View the new data at  
**TagrissoHCP.com**

AstraZeneca 

TAGRIS is a registered trademark of the AstraZeneca group of companies.  
©2019 AstraZeneca. All rights reserved. US-30110 9/19

The image depicted contains models and is being used for illustrative purposes only. Janssen R&D LLC. © JRD 2019



## A powerful way to fight cancer lives inside your body.

To fight cancer, we are developing immunotherapies that work with the body's natural defenses. Helping us get closer to a future where disease is a thing of the past. Learn more at [www.janssen.com](http://www.janssen.com)



### Open position: VP of Clinical Development or Medical Director



**REGOR** REGOR Pharmaceuticals Inc., Boston, MA [www.qlregor.com](http://www.qlregor.com)

Regor Pharmaceuticals is seeking a talented and motivated clinical expert to lead clinical trials to be conducted in the US and globally. The position will ideally be based in Boston, with the title of Medical Director or VP of Clinical Development, depending on level of experience.

Regor Pharmaceuticals is a pioneering international drug discovery company. With strong financial and organizational support, our mission is to deliver a steady flow of innovative therapeutic agents through internal drug research programs. We are now seeking a clinical expert to lead clinical development. He or she will strategically design and implement clinical trials by working closely with KOLs, clinical CROs and consulting firms. The candidate is required to have a medical degree or equivalent with experience and track record in conducting or overseeing clinical trials. His/her strong experience in oncology, autoimmune or metabolic disease is a plus. Strong communication and collaborative skills are expected for the candidate to work effectively with Regor colleagues and external collaborators.

Interested candidates please send your CV to Luyi Ji at [luyi.ji@qilu-pharma.com](mailto:luyi.ji@qilu-pharma.com) or [x.zhu@qlregor.com](mailto:x.zhu@qlregor.com).



CANCER HAS  
NO BORDERS.  
NEITHER  
DO WE<sup>®</sup>

Visit us at [www.beigene.com](http://www.beigene.com)



[www.linkedin.com/company/beigene](http://www.linkedin.com/company/beigene)



[@BeiGeneUSA](https://www.linkedin.com/company/beigene)



BeiGene



 **Tavalisse**<sup>®</sup>  
(fostamatinib disodium  
hexahydrate) tablets

LEARN MORE AT [TAVALISSEhcp.com](http://TAVALISSEhcp.com)



# Celebrating 25 Years of Progress for Patients

We are on a mission to help cancer patients  
recover stronger and live longer.

[www.exelixis.com](http://www.exelixis.com)

**EXELIXIS**<sup>®</sup>



Resilient  
Together



**Chinese American Hematologist and Oncologist Network (CAHON)**

555 East Wells Street, Suite 1100

Milwaukee, WI 53202 USA

Phone: 1 414-918-9890

Fax: 1 414-276-3349